Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer Driver

被引:57
|
作者
Wallace, Marsha D. [1 ,2 ]
Pfefferle, Adam D. [5 ,6 ]
Shen, Lishuang [1 ]
McNairn, Adrian J. [1 ]
Cerami, Ethan G. [8 ]
Fallon, Barbara L. [1 ]
Rinaldi, Vera D. [1 ]
Southard, Teresa L. [1 ,3 ]
Perou, Charles M. [5 ,6 ,7 ]
Schimenti, John C. [1 ,2 ,4 ]
机构
[1] Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA
[2] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA
[3] Cornell Univ, Sect Anat Pathol, Ithaca, NY 14853 USA
[4] Cornell Univ, Ctr Vertebrate Genom, Ithaca, NY 14853 USA
[5] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27514 USA
[6] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA
[7] Univ N Carolina, Dept Genet, Chapel Hill, NC 27514 USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
SOMATIC MUTATION; TUMOR; SUPPRESSOR; HETEROZYGOSITY; IDENTIFICATION; PROLIFERATION; REPLICATION; INSTABILITY; EXPRESSION; FRAMEWORK;
D O I
10.1534/genetics.112.142802
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Identifying genomic alterations driving breast cancer is complicated by tumor diversity and genetic heterogeneity. Relevant mouse models are powerful for untangling this problem because such heterogeneity can be controlled. Inbred Chaos3 mice exhibit high levels of genomic instability leading to mammary tumors that have tumor gene expression profiles closely resembling mature human mammary luminal cell signatures. We genomically characterized mammary adenocarcinomas from these mice to identify cancer-causing genomic events that overlap common alterations in human breast cancer. Chaos3 tumors underwent recurrent copy number alterations (CNAs), particularly deletion of the RAS inhibitor Neurofibromin 1 (Nf1) in nearly all cases. These overlap with human CNAs including NF1, which is deleted or mutated in 27.7% of all breast carcinomas. Chaos3 mammary tumor cells exhibit RAS hyperactivation and increased sensitivity to RAS pathway inhibitors. These results indicate that spontaneous NF1 loss can drive breast cancer. This should be informative for treatment of the significant fraction of patients whose tumors bear NF1 mutations.
引用
收藏
页码:385 / +
页数:25
相关论文
共 50 条
  • [1] Role of neurofibromin 1 (NF1) in myeloid cell control
    Clapp, DW
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 136 - 136
  • [2] NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy
    Cui, Xi-Wei
    Ren, Jie-Yi
    Gu, Yi-Hui
    Li, Qing-Feng
    Wang, Zhi-Chao
    CURRENT GENE THERAPY, 2020, 20 (02) : 100 - 108
  • [3] Neurofibromin (Nf1) is required for skeletal muscle development
    Kossler, Nadine
    Stricker, Sigmar
    Roedelsperger, Christian
    Robinson, Peter N.
    Kim, Johnny
    Dietrich, Carola
    Osswald, Monika
    Kuehnisch, Jirko
    Stevenson, David A.
    Braun, Thomas
    Mundlos, Stefan
    Kolanczyk, Mateusz
    HUMAN MOLECULAR GENETICS, 2011, 20 (14) : 2697 - 2709
  • [4] Multi-Omics Profiling for NF1 Target Discovery in Neurofibromin (NF1) Deficient Cells
    Carnes, Rachel M.
    Mobley, James A.
    Crossman, David K.
    Liu, Hui
    Korf, Bruce R.
    Kesterson, Robert A.
    Wallis, Deeann
    PROTEOMICS, 2019, 19 (11)
  • [5] Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia
    Giordano, MJ
    Mahadeo, DK
    He, YY
    Geist, RT
    Hsu, C
    Gutmann, DH
    JOURNAL OF NEUROSCIENCE RESEARCH, 1996, 43 (02) : 246 - 253
  • [6] Evolution and origin of neurofibromin, the product of the Neurofibromatosis type 1 (NF1) tumor-supressor gene
    Golovnina, K.
    Blinov, A.
    Chang, L-S
    PROCEEDINGS OF THE FIFTH INTERNATIONAL CONFERENCE ON BIOINFORMATICS OF GENOME REGULATION AND STRUCTURE, VOL 3, 2006, : 142 - +
  • [7] NEUROFIBROMIN (NF1) IS REQUIRED FOR NORMAL SKELETAL MUSCLE DEVELOPMENT
    Kolanczyk, M.
    Kossler, N.
    Stricker, S.
    Roedelsperger, C.
    Robinson, P. N.
    Kim, J.
    Dietrich, C.
    Osswald, M.
    Kuehnisch, J.
    Stevenson, D. A.
    Braun, T.
    Mundlos, S.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S563 - S563
  • [8] Neurofibromin (NF1) tumor suppressor gene functions as a GAP for Ras in T cells:: Functional and biochemical consequences of Nf1 heterozygosity and homozygosity.
    Kapur, R
    Zhang, L
    McCarthy, J
    Wenning, MJ
    Fisher, L
    Clapp, DW
    Ingram, D
    BLOOD, 2001, 98 (11) : 21A - 21A
  • [9] Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1 (NF1)
    Klose, A
    Ahmadian, MR
    Schuelke, M
    Scheffzek, K
    Hoffmeyer, S
    Gewies, A
    Schmitz, F
    Kaufmann, D
    Peters, H
    Wittinghofer, A
    Nurnberg, P
    HUMAN MOLECULAR GENETICS, 1998, 7 (08) : 1261 - 1268
  • [10] Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
    Annunziato, Stefano
    de Ruiter, Julian R.
    Henneman, Linda
    Brambillasca, Chiara S.
    Lutz, Catrin
    Vaillant, Francois
    Ferrante, Federica
    Drenth, Anne Paulien
    van der Burg, Eline
    Siteur, Bjorn
    van Gerwen, Bas
    de Bruijn, Roebi
    van Miltenburg, Martine H.
    Huijbers, Ivo J.
    van de Ven, Marieke
    Visvader, Jane E.
    Lindeman, Geoffrey J.
    Wessels, Lodewyk F. A.
    Jonkers, Jos
    NATURE COMMUNICATIONS, 2019, 10 (1)